Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer.
Saunders, Mark P
AffiliationDivision of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK
MetadataShow full item record
AbstractBackground: Constitutional loss of function (LOF) single nucleotide polymorphisms (SNPs) in pattern recognition receptors FPR1, TLR3, and TLR4 have previously been reported to predict oxaliplatin benefit in colorectal cancer. Confirmation of this association could substantially improve patient stratification. Methods: We performed a retrospective biomarker analysis of the Short Course in Oncology Therapy (SCOT) and COIN/COIN-B trials. Participant status for LOF variants in FPR1 (rs867228), TLR3 (rs3775291), and TLR4 (rs4986790/rs4986791) was determined by genotyping array or genotype imputation. Associations between LOF variants and disease-free survival (DFS) and overall survival (OS) were analyzed by Cox regression, adjusted for confounders, using additive, dominant, and recessive genetic models. All statistical tests were two-sided. Results: Our validation study populations included 2929 and 1948 patients in the SCOT and COIN/COIN-B cohorts, respectively, of whom 2728 and 1672 patients had functional status of all three SNPs determined. We found no evidence of an association between any SNP and DFS in the SCOT cohort, or with OS in either cohort, irrespective of the type of model used. This included models for which an association was previously reported for rs867228 (recessive model, multivariable-adjusted hazard ratio [HR] for DFS in SCOT?=?1.19, 95% confidence interval [CI]?=?0.99 to 1.45, P?=?.07; HR for OS in COIN/COIN-B?=?0.92, 95% CI?=?0.63 to 1.34, P?=?.66), and rs4986790 (dominant model, multivariable-adjusted HR for DFS in SCOT?=?0.86, 95% CI?=?0.65 to 1.13, P?=?.27; HR for OS in COIN/COIN-B?=?1.08, 95% CI?=?0.90 to 1.31, P?=?.40). Conclusion: In this prespecified analysis of two large clinical trials, we found no evidence that constitutional LOF SNPs in FPR1, TLR3, or TLR4 are associated with differential benefit from oxaliplatin. Our results suggest these SNPs are unlikely to be clinically useful biomarkers.
CitationGray V, Briggs S, Palles C, Jaeger E, Iveson T, Kerr R, et al. Pattern recognition receptor polymorphisms as predictors of oxaliplatin benefit in colorectal cancer. J Natl Cancer Inst. 2019 Jan 14.
JournalJournal of the National Cancer Institute
- Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
- Authors: Summers MG, Maughan TS, Kaplan R, Law PJ, Houlston RS, Escott-Price V, Cheadle JP
- Issue date: 2020 Jan
- A Prospective Evaluation of the Association between a Single Nucleotide Polymorphism rs3775291 in Toll-Like Receptor 3 and Breast Cancer Relapse.
- Authors: Chen DN, Song CG, Yu KD, Jiang YZ, Ye FG, Shao ZM
- Issue date: 2015
- Association of Genetic Polymorphisms in <i>TLR3</i>, <i>TLR4</i>, <i>TLR7</i>, and <i>TLR8</i> with the Clinical Forms of Dengue in Patients from Veracruz, Mexico.
- Authors: Posadas-Mondragón A, Aguilar-Faisal JL, Zuñiga G, Magaña JJ, Santiago-Cruz JA, Guillén-Salomón E, Alcántara-Farfán V, Arellano-Flores ML, Salas-Benito JS, Neri-Bazán RM, Luna-Rojas L, Avila-Trejo AM, Chávez-Negrete A
- Issue date: 2020 Oct 29
- 3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCT.
- Authors: Iveson T, Boyd KA, Kerr RS, Robles-Zurita J, Saunders MP, Briggs AH, Cassidy J, Hollander NH, Tabernero J, Haydon A, Glimelius B, Harkin A, Allan K, McQueen J, Pearson S, Waterston A, Medley L, Wilson C, Ellis R, Essapen S, Dhadda AS, Harrison M, Falk S, Raouf S, Rees C, Olesen RK, Propper D, Bridgewater J, Azzabi A, Farrugia D, Webb A, Cunningham D, Hickish T, Weaver A, Gollins S, Wasan H, Paul J
- Issue date: 2019 Dec
- Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.
- Authors: Tokunaga R, Cao S, Naseem M, Lo JH, Battaglin F, Puccini A, Berger MD, Soni S, Millstein J, Zhang W, Stintzing S, Loupakis F, Cremolini C, Heinemann V, Falcone A, Lenz HJ
- Issue date: 2019 Mar